Latest Insider Transactions at Neuro Pace Inc (NPCE)
This section provides a real-time view of insider transactions for Neuro Pace Inc (NPCE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NeuroPace Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NeuroPace Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 22
2023
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
179
-0.12%
|
$1,074
$6.88 P/Share
|
|
Oct 03
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
700
-0.02%
|
$6,300
$9.02 P/Share
|
|
Oct 02
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
7,614
-0.19%
|
$68,526
$9.08 P/Share
|
|
Sep 03
2023
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,302
-1.67%
|
$10,416
$8.93 P/Share
|
|
Sep 03
2023
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,010
-0.69%
|
$8,080
$8.93 P/Share
|
|
Jul 22
2023
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
231
-0.29%
|
$924
$4.13 P/Share
|
|
Jul 22
2023
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
179
-0.12%
|
$716
$4.13 P/Share
|
|
Jun 03
2023
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,303
-1.63%
|
$5,212
$4.11 P/Share
|
|
Jun 03
2023
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,010
-0.69%
|
$4,040
$4.11 P/Share
|
|
Apr 22
2023
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
231
-0.29%
|
$924
$4.25 P/Share
|
|
Apr 22
2023
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
179
-0.12%
|
$716
$4.25 P/Share
|
|
Mar 03
2023
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
5,167
-6.07%
|
$20,668
$4.1 P/Share
|
|
Mar 03
2023
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
4,019
-2.66%
|
$16,076
$4.1 P/Share
|
|
Feb 21
2023
|
Michael Favet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
225,000
+35.6%
|
-
|
|
Feb 20
2023
|
Irina Ridley Chief Legal Officer/Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+36.18%
|
-
|
|
Feb 20
2023
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+36.41%
|
-
|
|
Feb 20
2023
|
Martha Morrell CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+36.84%
|
-
|
|
Jan 22
2023
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
264
-0.31%
|
$528
$2.98 P/Share
|
|
Jan 22
2023
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
212
-0.14%
|
$424
$2.98 P/Share
|
|
Nov 22
2022
|
Accelmed Partners Ii L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
62,398
+1.39%
|
$62,398
$1.5 P/Share
|
|
Nov 21
2022
|
Accelmed Partners Ii L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
327,893
+6.98%
|
$327,893
$1.5 P/Share
|
|
Oct 31
2022
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,428
+0.8%
|
$0
$0.03 P/Share
|
|
Oct 22
2022
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
233
-0.27%
|
$699
$3.02 P/Share
|
|
Oct 22
2022
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
181
-0.12%
|
$543
$3.02 P/Share
|
|
Oct 18
2022
|
Joseph Lacob |
BUY
Exercise of conversion of derivative security
|
Direct |
192
+33.33%
|
$0
$0.03 P/Share
|
|
Oct 07
2022
|
Martha Morrell CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
576
+0.5%
|
$0
$0.03 P/Share
|
|
Jul 22
2022
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
231
-0.27%
|
$1,155
$5.55 P/Share
|
|
Jul 22
2022
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
179
-0.12%
|
$895
$5.55 P/Share
|
|
Jun 08
2022
|
Irina Ridley Chief Legal Officer/Secretary |
SELL
Open market or private sale
|
Direct |
2,500
-3.93%
|
$12,500
$5.78 P/Share
|
|
Apr 22
2022
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
926
-1.07%
|
$7,408
$8.32 P/Share
|
|
Apr 22
2022
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
718
-0.47%
|
$5,744
$8.32 P/Share
|
|
Mar 08
2022
|
Michael Favet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
155,080
+46.0%
|
-
|
|
Mar 03
2022
|
Martha Morrell CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
46,760
+45.25%
|
-
|
|
Mar 03
2022
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
46,740
+44.51%
|
-
|
|
Mar 03
2022
|
Irina Ridley Chief Legal Officer/Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
56,987
+47.24%
|
-
|
|
Feb 28
2022
|
Irina Ridley Chief Legal Officer/Secretary |
SELL
Open market or private sale
|
Direct |
1,470
-18.1%
|
$10,290
$7.54 P/Share
|
|
Jun 04
2021
|
Irina Ridley Chief Legal Officer/Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
5,681
+41.42%
|
-
|
|
Jun 04
2021
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
8,181
+41.77%
|
-
|
|
Jun 04
2021
|
Michael Favet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,590
+50.0%
|
-
|
|
Jun 04
2021
|
Martha Morrell CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
8,181
+45.76%
|
-
|
|
Apr 26
2021
|
Joseph Lacob |
BUY
Grant, award, or other acquisition
|
Indirect |
334,027
+48.7%
|
-
|
|
Apr 26
2021
|
Michael Favet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
15,385
+40.14%
|
$0
$0.03 P/Share
|
|
Apr 26
2021
|
Michael Favet Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
7,562
+50.0%
|
-
|
|
Apr 26
2021
|
Greg Shaw Garfield Director |
BUY
Conversion of derivative security
|
Indirect |
5,614,384
+49.96%
|
-
|
|
Apr 26
2021
|
Accelmed Partners Ii L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,454,422
+46.08%
|
-
|
|
Apr 26
2021
|
Evan Norton Director |
BUY
Conversion of derivative security
|
Indirect |
3,454,422
+46.08%
|
-
|
|
Apr 26
2021
|
Frank M Fischer |
BUY
Conversion of derivative security
|
Direct |
472,366
+45.51%
|
-
|
|
Apr 26
2021
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,777,281
+48.49%
|
-
|
|
Apr 26
2021
|
Kck Ltd. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
5,595,493
+49.89%
|
-
|
|
Apr 21
2021
|
Evan Norton Director |
BUY
Open market or private purchase
|
Indirect |
588,235
+50.0%
|
$9,999,995
$17.0 P/Share
|